- Home
- CVKD vs RLYB Comparison
CVKD vs RLYB Comparison
Compare CVKD & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- RLYB
- Stock Information
- Founded
- CVKD 2022
- RLYB 2018
- Country
- CVKD United States
- RLYB United States
- Employees
- CVKD N/A
- RLYB N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- RLYB Health Care
- Exchange
- CVKD Nasdaq
- RLYB Nasdaq
- Market Cap
- CVKD 34.2M
- RLYB 28.9M
- IPO Year
- CVKD 2023
- RLYB 2021
- Fundamental
- Price
- CVKD $17.77
- RLYB $0.66
- Analyst Decision
- CVKD Strong Buy
- RLYB Buy
- Analyst Count
- CVKD 1
- RLYB 5
- Target Price
- CVKD $32.00
- RLYB $9.75
- AVG Volume (30 Days)
- CVKD 44.3K
- RLYB 56.1K
- Earning Date
- CVKD 05-08-2025
- RLYB 05-08-2025
- Dividend Yield
- CVKD N/A
- RLYB N/A
- EPS Growth
- CVKD N/A
- RLYB N/A
- EPS
- CVKD N/A
- RLYB N/A
- Revenue
- CVKD N/A
- RLYB $598,000.00
- Revenue This Year
- CVKD N/A
- RLYB N/A
- Revenue Next Year
- CVKD N/A
- RLYB N/A
- P/E Ratio
- CVKD N/A
- RLYB N/A
- Revenue Growth
- CVKD N/A
- RLYB N/A
- 52 Week Low
- CVKD $5.40
- RLYB $0.62
- 52 Week High
- CVKD $22.90
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- CVKD 49.27
- RLYB 36.23
- Support Level
- CVKD $14.64
- RLYB $0.62
- Resistance Level
- CVKD $17.58
- RLYB $0.75
- Average True Range (ATR)
- CVKD 1.86
- RLYB 0.06
- MACD
- CVKD -0.29
- RLYB -0.00
- Stochastic Oscillator
- CVKD 39.10
- RLYB 17.83
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.